We developed a novel combined treatment comprising RT and administration of the Toll-like receptor 3 (TLR3) agonist poly(I:C) in a noninvasive manner to enhance the abscopal effect in HCC. This evidence concerns the gene TLR3 and hepatocellular carcinoma.